ATE339966T1 - Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten - Google Patents

Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten

Info

Publication number
ATE339966T1
ATE339966T1 AT98930436T AT98930436T ATE339966T1 AT E339966 T1 ATE339966 T1 AT E339966T1 AT 98930436 T AT98930436 T AT 98930436T AT 98930436 T AT98930436 T AT 98930436T AT E339966 T1 ATE339966 T1 AT E339966T1
Authority
AT
Austria
Prior art keywords
graft
compositions
primates
pancreas
cell transplantation
Prior art date
Application number
AT98930436T
Other languages
English (en)
Inventor
Norma S Kenyon
Camillo Ricordi
David W Thomas
Linda Burkly
Original Assignee
Biogen Idec Inc
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ Miami filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE339966T1 publication Critical patent/ATE339966T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)
AT98930436T 1997-06-20 1998-06-19 Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten ATE339966T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US7726598P 1998-03-09 1998-03-09

Publications (1)

Publication Number Publication Date
ATE339966T1 true ATE339966T1 (de) 2006-10-15

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930436T ATE339966T1 (de) 1997-06-20 1998-06-19 Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten

Country Status (22)

Country Link
US (2) US20030072754A1 (de)
EP (1) EP1051191B1 (de)
JP (1) JP2002506446A (de)
KR (1) KR100634847B1 (de)
CN (2) CN1195546C (de)
AT (1) ATE339966T1 (de)
AU (1) AU730763B2 (de)
BG (1) BG64976B1 (de)
BR (1) BR9810620A (de)
CA (1) CA2294154A1 (de)
DE (1) DE69835965T2 (de)
EA (1) EA002550B1 (de)
EE (1) EE9900588A (de)
HK (1) HK1033548A1 (de)
HU (1) HUP0003160A3 (de)
IL (1) IL133303A0 (de)
IS (1) IS5273A (de)
NO (1) NO996275L (de)
NZ (1) NZ502052A (de)
SK (1) SK180299A3 (de)
TR (1) TR199903142T2 (de)
WO (1) WO1998058669A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1289554A4 (de) * 2000-06-02 2004-05-26 Univ Minnesota Immunotherapeutische methode zur vermeidung der abstossung von inselzellen
AU2001275411B2 (en) * 2000-06-09 2005-04-28 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
EP1814980B1 (de) * 2004-11-22 2015-03-25 Ramot at Tel-Aviv University Ltd. Populationen expandierter und rückdifferenzierter adulter beta-inselzellen mit der fähigkeit zur produktion von insulin sowie verfahren zur erzeugung davon
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
BG64976B1 (bg) 2006-11-30
BR9810620A (pt) 2000-10-03
AU7983098A (en) 1999-01-04
WO1998058669A2 (en) 1998-12-30
HUP0003160A3 (en) 2002-09-30
NO996275D0 (no) 1999-12-17
US20070292440A1 (en) 2007-12-20
CN1195546C (zh) 2005-04-06
EP1051191B1 (de) 2006-09-20
EA002550B1 (ru) 2002-06-27
DE69835965D1 (de) 2006-11-02
JP2002506446A (ja) 2002-02-26
US20030072754A1 (en) 2003-04-17
KR20010013965A (ko) 2001-02-26
KR100634847B1 (ko) 2006-10-17
WO1998058669A3 (en) 1999-04-29
DE69835965T2 (de) 2007-06-14
IS5273A (is) 1999-11-26
CN1261286A (zh) 2000-07-26
EP1051191A2 (de) 2000-11-15
IL133303A0 (en) 2001-04-30
NZ502052A (en) 2001-01-26
BG104091A (en) 2000-10-31
EA200000058A1 (ru) 2000-08-28
AU730763B2 (en) 2001-03-15
HK1033548A1 (en) 2001-09-07
CA2294154A1 (en) 1998-12-30
CN1651919A (zh) 2005-08-10
NO996275L (no) 2000-02-21
EE9900588A (et) 2000-08-15
HUP0003160A2 (hu) 2001-01-29
SK180299A3 (en) 2000-06-12
TR199903142T2 (xx) 2000-09-21

Similar Documents

Publication Publication Date Title
ATE339966T1 (de) Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten
EP0163475A3 (en) Immunoregulation
DK1189629T3 (da) Peptid YY (PYY) til behandling af glucosestofskiftesygdomme
DE69434588D1 (de) Verzögerte Freigabe von Insulinotropin (GLP-1)
DE60143517D1 (de) Wiederherstellung der gelenken mit mesenchymalen stammzellen
CA2320040A1 (en) Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
WO2006012404A3 (en) Novel cell populations and uses thereof
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
HARRIS et al. Immunodeficiency in chronic uremia: Preliminary evidence for thymosin deficiency
BR0309624A (pt) Uso de xenÈnio para o controle de deficiências neurológicas associadas com desvio cardiopulmonar
IL95046A0 (en) Substituted 2-imidazolines and pharmaceutical compositions containing them
GR930300003T1 (en) Inhibitor of proliferation of endothelial cells.
EP1754490A3 (de) CD154-Blockadetherapie der Pankreasinselzellentransplantation bei Primaten
NZ237739A (en) Pharmaceutical composition of a complement inhibitor and an immunosuppressant with cyclosporin a-like activity, and its use
Egel et al. Renal failure in heart transplant patients receiving cyclosporine.
WO2001051093A3 (en) METHODS OF INCREASING THE GLUCOSE RESPONSIVENESS OF PANCREATIC β-CELLS
EP0886528A4 (de) Verwendung Von Coxiella Bakterien zur Behandlung von Autoimmunkrankheiten
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет
AU641538B2 (en) Method for the preparation of sulphinyl pristinamycin IIB
ZA939227B (en) Novel triazoloquinazolines,their preparation and use
NO950114L (no) Amylin-antagonister og agonister
IT8820921A0 (it) Struttura meccanica polivalente, in particolare per salvataggio e sopravvivenza.
Luck To Clarence Hemingway, 26 September [1918]
Ernster Wanderings in bioenergetics with Licio Azzone.
刘洪琪 et al. The effect analysis of functional anaplasty in the position of arthrogryposis during the late period of super-large burn

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1051191

Country of ref document: EP

REN Ceased due to non-payment of the annual fee